Secondary analyses showed that median OS was significantly longer for patients receiving masitinib followed by post-progression addition of sunitinib when compared against patients treated directly with sunitinib in second-line -LSB- hazard ratio ( HR ) = @ , @ % CI @-@ @ , P = @ -RSB- .